Group items tagged

Tobacco use remains the leading preventable cause of disease and death in the United States. More than half of smokers attempt to quit each year, but fewer than one in ten succeed. Evidence-based cessation treatments, including individual, group, and telephone counseling and seven FDA-approved cessation medications, exist, but are underutilized. The Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health is announcing the opportunity to apply for funds for a competitive, non-research cooperative agreement to provide technical assistance to state tobacco control programs and other partners to translate the science of tobacco control cessation into public health action in order to further increase the rate of cessation among tobacco users in the United States. The funded organizations will accomplish this by providing technical assistance to state tobacco control programs and other partners to 1) Implement health systems change initiatives that seek to integrate tobacco dependence treatment into routine clinical care, including care of persons with behavioral health conditions; and 2) Improve state quitlines' infrastructure, operations, and services to further enhance their effectiveness and efficiency, increase state quitlines' reach, especially among populations experiencing tobacco-related disparities, broaden the range of cessation services offered by state quitlines, and enhance quitline sustainability.

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use cancer health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce cancer health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing cancer health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use cancer health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce cancer health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

Cigarette smoking and exposure to secondhand smoke (SHS) is the leading preventable cause of death in the United States, resulting in approximately 480,000 premature deaths and 16 million smoking-related illnesses. Cigarette smoking can lead to increased cardiovascular disease, multiple types of cancer, pulmonary disease, adverse reproductive outcomes, and the exacerbation of chronic health conditions. Annual costs associated with tobacco-related illnesses amount to nearly $280 billion in medical expenses and lost productivity. Electronic cigarette (e-cigarette) use among U.S. youth and young adults has increased considerably, growing 900% among high school students from 2011 to 2015. Cancer is the second leading cause of death in the United States, with approximately 1.5 million new diagnoses and over 550,000 deaths each year. Commercial Tobacco use is the leading preventable cause of cancer and cancer deaths. It can cause not only lung cancer but also cancers of the mouth and throat, voice box, esophagus, stomach, kidney, pancreas, liver, bladder, cervix, colon and rectum, and a type of leukemia.

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra

A cancer survivor is a person diagnosed with cancer, from the time of diagnosis throughout the person’s lifespan. As of 2008, nearly 12 million cancer survivors were living in the United States; this number is expected to increase to 18 million in 2020. Cancer survivors have long-term adverse physical and psychosocial effects from their diagnosis and treatment, and have a greater risk for additional cancer diagnoses compared with persons without a cancer history. Cancer survivors commonly report negative behavioral, medical, and health care access issues that may contribute to poor long-term medical and psychosocial outcomes. An analysis of over 45,000 U.S. cancer survivors showed that: 1) 15% of cancer survivors continue to use tobacco; 2) 20-25% do not receive recommended cancer screenings; 3) 31% do not engage in any leisure time physical activity; 4) 40 to 50% do not receive flu or pneumonia vaccines; 5) 60% do not have a summary of their cancer treatment; and 6) 25% do not have any instructions (written or oral) for their treatment or follow-up care . CDC’s National Comprehensive Cancer Control Program (NCCCP) supports collaborative cancer control and prevention efforts in all states, the District of Columbia, tribal organizations, territories, and Pacific Island jurisdictions to address the cancer burden in their jurisdictions. In 2010, NCCCP developed six priorities areas of focus for the greatest public health impact; one of the six priorities is to address the public health needs of cancer survivors. The purpose of this FOA is to implement a broad set of evidence-based survivorship strategies in a subset of NCCCP grantees that will have the short-term results of increasing knowledge of cancer survivor needs, increasing survivor knowledge of treatment and follow-up care, and increasing provider knowledge of guidelines pertaining to treatment of cancer. Intermediate outcomes include the development of best practices in survivorship among NCCCP gra